<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133665</url>
  </required_header>
  <id_info>
    <org_study_id>09-206-B</org_study_id>
    <nct_id>NCT01133665</nct_id>
  </id_info>
  <brief_title>Cetuximab and Lenalidomide in Head and Neck</brief_title>
  <official_title>Phase II Study of Cetuximab and Lenalidomide in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study specific FcRIIIa polymorphisms and their correlation
      with clinical outcome in subjects treated with cetuximab and lenalidomide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To study specific FcRIIIa polymorphisms and their correlation with clinical outcome in
      subjects treated with cetuximab and lenalidomide. There is evidence with cetuximab in CRC,
      trastuzumab in breast cancer and rituximab with follicular lymphoma, that FcRIIIa
      polymorphisms correlate with clinical response to antibody therapy and clinical outcome. It
      is our hypothesis that patients with SCCHN will have clinical outcomes to cetuximab and
      lenalidomide that correlate with patient FcRIIIa genotype.

      Secondary:

      To evaluate the safety and toxicity profile of the combination of cetuximab and lenalidomide
      given to treat subjects with SCCHN.

      To study FcRIIIa polymorphisms and the correlation with the ability of NK cells to mediate
      ADCC against SCCHN. It is our hypothesis that NK cells from patients with advanced SCCHN can
      mediate ADCC against SCCHN cell lines in the presence of cetuximab and lenalidomide and that
      the efficiency of ADCC correlates with FcRIIIa polymorphisms.

      To evaluate the ability of NK cells to induce ADCC expression of specific activation markers
      on the NK cell surface. It is our hypothesis that NK cells that induce ADCC will express
      specific activation markers that are predictive of efficiency of ADCC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlate the Presence of Specific Fc RIIIa Polymorphisms With Progression-free Survival in Subjects Receiving Cetuximab and Lenalidomide for SCCHN.</measure>
    <time_frame>24 months</time_frame>
    <description>Progression-free survival (PFS) was defined as time from date of the first treatment dose administered to the earlier of disease progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Fatigue Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Maculopapular Rash Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Constipation Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anemia Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anorexia Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Nausea Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hypoalbuminemia Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Lymphopenia Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Oral Mucositis Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pain Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Vomiting Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With White Blood Cell Decreased Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Diarrhea Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hyponatremia Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neutropenia Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Headache Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hypokalemia Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hypophosphatemia Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Thrombocytopenia Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acneiform Rash Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hyperglycemia Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Alkaline Phosphatase Increased Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Aspartate Aminotransferase Increased Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Xerostomia Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Fever Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hypocalcaemia Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neck Pain Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Peripheral Sensory Neuropathy Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Alanine Aminotransferase Increased Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Back Pain Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Dyspnea Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Weight Loss Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Blood Bilirubin Increased Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infusion Related Reaction Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With C. Diff Infection Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Febrile Neutropenia Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Lymphocyte Count Increased Related to Cetuximab/Lenalidomide</measure>
    <time_frame>24 month</time_frame>
    <description>Toxicity was scored according to NCI/CTC version 4</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sub Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All Subjects Enrolled in the Trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab and Lenalidomide</intervention_name>
    <description>The treatment of Head and Neck Cancer with Cetuximab and Lenalidomide</description>
    <arm_group_label>Sub Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Understand and voluntarily sign an informed consent form.

          2. Age ≥18 years at the time of signing the informed consent form.

          3. Able to adhere to the study visit schedule and other protocol requirements.

          4. Recurrent or metastatic squamous cell or undifferentiated carcinoma of the head and
             neck that is not amenable to curative therapy. Patients who are candidates for local
             or locoregional therapy should not be deprived of proven beneficial palliative
             therapies.

          5. All previous cancer therapy, including radiation, hormonal therapy, EGFR inhibitors,
             and surgery, must have been discontinued at least 4 weeks prior to treatment in this
             study.

          6. ECOG performance status of 0-1 at study entry.

          7. Laboratory test results within these ranges:

               -  Absolute neutrophil count to ≥ 1000/mm³

               -  Platelet count ≥ 100,000/mm³

               -  Calculated creatinine clearance ≥ 50ml/min by Cockcroft-Gault estimation

               -  Total bilirubin &lt; 1.5 x ULN

               -  AST (SGOT) and ALT (SGPT) &lt; 3 x ULN or &lt; 5 x ULN if hepatic metastases are
                  present.

          8. Disease free of prior malignancies for &lt; 3 years with exception of currently treated
             basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in-situ&quot; of the cervix
             or breast. Patients with malignancies diagnosed less than 3 years prior to study entry
             are eligible if the first cancer was no greater than stage I and did not recur.
             Patients with malignancies diagnosed less than 3 years prior to study entry must have
             the diagnosis of recurrent or metastatic squamous cell carcinoma of the head and neck
             confirmed pathologically.

          9. All study participants must be registered into the mandatory RevAssist® program, and
             be willing and able to comply with the requirements of RevAssist®.

         10. Females of childbearing potential (FCBP)† must have a negative serum or urine
             pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
             and again within 24 hours of prescribing lenalidomide (prescriptions must be filled
             within 7 days) and must either commit to continued abstinence from heterosexual
             intercourse or begin TWO acceptable methods of birth control, one highly effective
             method and one additional effective method AT THE SAME TIME, at least 28 days before
             she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men
             must agree to use a latex condom during sexual contact with a FCBP even if they have
             had a successful vasectomy. See Appendix: Risks of Fetal Exposure, Pregnancy Testing
             Guidelines and Acceptable Birth Control Methods.

         11. Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients
             intolerant to ASA may use warfarin or low molecular weight heparin).

         12. Measurable disease, defined as at least one lesion that can be accurately measured in
             at least one dimension (longest diameter to be recorded), with minimum lesion size ≥ 2
             cm on conventional measurement techniques or ≥ 1 cm on spiral computed tomography (CT)
             scan. Lesions that can be measured clinically must be at least 1 cm in greatest
             dimension by caliper measurement.

        Exclusion Criteria:

          1. Primary head and neck carcinomas of the salivary gland, skin, or thyroid regardless of
             pathology

          2. Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          3. Pregnant or breast feeding females. (Lactating females must agree not to breast feed
             while taking lenalidomide).

          4. Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study.

          5. Use of any other experimental drug or therapy within 28 days of baseline.

          6. Prior therapy with lenalidomide for squamous cell carcinoma of the head and neck

          7. Known hypersensitivity to thalidomide.

          8. The development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide or similar drugs.

          9. Concurrent use of other anti-cancer agents or treatments.

         10. Known positive for HIV or infectious hepatitis, type B or C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Everett Vokes, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://uccrc.uchicago.edu/</url>
    <description>The University of Chicago Cancer Research Center Website</description>
  </link>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2010</study_first_posted>
  <results_first_submitted>November 17, 2014</results_first_submitted>
  <results_first_submitted_qc>November 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 24, 2014</results_first_posted>
  <last_update_submitted>November 17, 2014</last_update_submitted>
  <last_update_submitted_qc>November 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck, Squamous Cell</keyword>
  <keyword>Recurrent or metastatic squamous cell or undifferentiated carcinoma of the head and neck that is not amenable to curative therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cetuximab and Lenalidomide</title>
          <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cetuximab and Lenalidomide</title>
          <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="42" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Correlate the Presence of Specific Fc RIIIa Polymorphisms With Progression-free Survival in Subjects Receiving Cetuximab and Lenalidomide for SCCHN.</title>
        <description>Progression-free survival (PFS) was defined as time from date of the first treatment dose administered to the earlier of disease progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Correlate the Presence of Specific Fc RIIIa Polymorphisms With Progression-free Survival in Subjects Receiving Cetuximab and Lenalidomide for SCCHN.</title>
          <description>Progression-free survival (PFS) was defined as time from date of the first treatment dose administered to the earlier of disease progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.0" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Fatigue Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fatigue Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Maculopapular Rash Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Maculopapular Rash Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Constipation Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Constipation Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anemia Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anemia Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anorexia Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anorexia Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Nausea Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Nausea Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hypoalbuminemia Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypoalbuminemia Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Lymphopenia Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Lymphopenia Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Oral Mucositis Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Oral Mucositis Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Pain Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pain Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Vomiting Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vomiting Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With White Blood Cell Decreased Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With White Blood Cell Decreased Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Diarrhea Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Diarrhea Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hyponatremia Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hyponatremia Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neutropenia Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neutropenia Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Headache Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Headache Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hypokalemia Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypokalemia Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hypophosphatemia Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypophosphatemia Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Thrombocytopenia Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Thrombocytopenia Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acneiform Rash Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acneiform Rash Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hyperglycemia Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hyperglycemia Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Alkaline Phosphatase Increased Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Alkaline Phosphatase Increased Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Aspartate Aminotransferase Increased Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Aspartate Aminotransferase Increased Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Xerostomia Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 3</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Xerostomia Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 3</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Fever Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fever Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hypocalcaemia Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypocalcaemia Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neck Pain Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neck Pain Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Peripheral Sensory Neuropathy Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Peripheral Sensory Neuropathy Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Alanine Aminotransferase Increased Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Alanine Aminotransferase Increased Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Back Pain Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Back Pain Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Dyspnea Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dyspnea Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Weight Loss Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Weight Loss Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Blood Bilirubin Increased Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Blood Bilirubin Increased Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infusion Related Reaction Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infusion Related Reaction Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With C. Diff Infection Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With C. Diff Infection Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Febrile Neutropenia Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Febrile Neutropenia Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Lymphocyte Count Increased Related to Cetuximab/Lenalidomide</title>
        <description>Toxicity was scored according to NCI/CTC version 4</description>
        <time_frame>24 month</time_frame>
        <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab and Lenalidomide</title>
            <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Lymphocyte Count Increased Related to Cetuximab/Lenalidomide</title>
          <description>Toxicity was scored according to NCI/CTC version 4</description>
          <population>Analysis Population Description: The number of participants for analysis was determined with &gt;5% incidence of adverse events or any grade 3–4 adverse events related to cetuximab/lenalidomide</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cetuximab and Lenalidomide</title>
          <description>Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated wıth cetuximab (500 mg/m2 IV every 2 weeks) and lenalidomide (25 mg orally or via feeding tube once daily)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Trismus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Papulopustular rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Everett Vokes</name_or_title>
      <organization>The University of Chicago</organization>
      <phone>773-702-9306</phone>
      <email>evokes@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

